Global edition
Region
NewsWebcastsPodcastsThe Magazine
Sign inSubscribe
Follow Pharma Now@pharmanow.live
Editions & local coverage
United StatesUnited KingdomGermanyFranceItalyIndiaSwitzerlandSingapore

A global knowledge and leadership platform for pharma. We turn complexity into clarity professionals can act on.

Get the Pharma Now app

Read offline, save stories and never miss an edition.

Get it onGoogle PlayDownload on theApp Store
Verticals
  • Microbiology & CCS
  • Pharma IT
  • Pharma Marketing
  • Regulatory Intelligence
  • Bio Pharma
  • Future Pharma Trends
Formats
  • News & Analysis
  • Interviews
  • Webcasts
  • Podcasts
  • Events
  • Magazine
Knowledge Hub
  • Knowledge Hub
  • Research Papers
  • Buyer’s Guides
  • Companies
  • Newsletter Archive
  • Glossary
Company
  • Advisory Board
  • Contributors
  • Write for Us
  • Submit a PR
  • Contact
  • Advertise
Account
  • Subscribe
  • Sign in
  • My Account
Frequently asked

Pharma Now is a leading monthly B2B magazine focused on delivering in-depth content related to the pharmaceutical and biopharma sectors. It covers the latest trends, technological innovations, leadership insights, market developments, and interviews with industry experts.

Pharma Now provides comprehensive coverage, including: - Industry news and updates - Interviews with global pharma leaders - Market insights and trends - Innovations in AI, manufacturing, and pharma operations - Case studies, thought leadership articles, and regulatory updates

Pharma Now caters to a wide range of professionals within the pharmaceutical industry, including C-level executives, R&D professionals, quality managers, regulatory affairs specialists, and business leaders looking to stay informed about global trends and innovations.

You can subscribe to Pharma Now by visiting the Pharma Now website and choosing between print and digital editions.

Yes, Pharma Now welcomes contributions from industry experts. Contributors can submit articles, thought leadership pieces, and case studies. You can register on the contributors' page to submit content and gain recognition for your insights.

Pharma Now offers multiple advertising packages tailored to help companies promote their products, services, and innovations. From full-page ads to special event coverage, advertisers can reach a targeted audience of pharma professionals. For details, visit the Advertise With Us section on the website.

Copyright © 2026 Tantragyan Technologies Pvt Ltd. All Rights Reserved.
Privacy PolicyTerms of UseContact UsAdvertise
Home/News
NewsAI-assisted

RADIAN Expands HIV Support in Eastern Europe and Central Asia

RADIAN funds HIV projects in EECA, expanding to support Ukrainian refugees needing HIV care.

Mrudula Kulkarni
By Mrudula Kulkarni
Managing Editor - Pharma Now
Jul 22, 2024Updated Jun 26, 2025 · 2 min read
Share
RADIAN Expands HIV Support in Eastern Europe and Central Asia
https://www.gilead.com/purpose/partnerships-and-community/radian
AI-assisted reporting
Reviewed by Mrudula Kulkarni, Managing Editor - Pharma Now

A five-year extension of the RADIAN® cooperation between Gilead Sciences, Inc. and the Elton John AIDS Foundation (EJAF) has been announced in order to better serve the needs of critical populations in Eastern Europe and Central Asia (EECA), where the HIV pandemic is spreading. The collaboration will keep helping community-based groups tackling HIV-related issues in the area. Even though the number of HIV cases worldwide is down, the EECA is one of the few places where the pandemic is worsening. Since 2010, the number of new cases and AIDS-related fatalities has increased by 20% and 34%, respectively. Out of the 2.1 million HIV-positive individuals in the EECA, 41% do not know they have the virus, and 50% are not receiving treatment—well below the worldwide objectives of 95-95-95-95.

Daniel O'Day, Chairman and CEO of Gilead Sciences, stressed the need of intensifying cooperative efforts over the following five years. With over 271,000 individuals receiving HIV services, over 114,000 HIV tests given, over 26,500 people starting antiretroviral medication, and over 14,000 frontline workers trained to lessen stigma and prejudice, RADIAN has made a substantial contribution to the region's HIV response. Nonetheless, the crisis in Ukraine, anti-LGBTQ+ laws, abuses of human rights, stigma, and discrimination have all contributed to a sharp increase in the situation in the region in recent years.

Throughout Eastern Europe and Central Asia, an area that is sometimes disregarded in the global HIV response, the Elton John AIDS Foundation has a long history of providing support to persons living with or at risk of HIV. In order to address the needs of the most vulnerable key groups in the EECA, such as drug users, men who have sex with men, sex workers, and transgender individuals, RADIAN will continue to fund cooperative, community-based projects for the next five years. Additionally, RADIAN will broaden its geographic scope to include nations that are now sheltering refugees from Ukraine, a region that has a dire need for more HIV care. Through improved access to HIV services and support for their social and mental welfare, this expansion will give these vulnerable populations additional assistance. 


TopicsNews
Mrudula Kulkarni
Written by
Mrudula Kulkarni
Managing Editor - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.



Discussion

Loading discussion…

Trending now

1

Tonix Plans Adaptive Phase 2 Trial for Seasonal Lyme Disease Prevention Therapy, Advances Program Following FDA Type C Meeting

News · Aug 04, 2026
2

Medicus Pharma Appoints Dr. Faisal Mehmud as CEO of UK Subsidiary Antev, Strengthens Leadership to Advance Global Development of Teverelix®

News · Aug 04, 2026
3

Acurx Receives Positive FDA Feedback on Ibezapolstat Phase 3 Development Program, FDA Signals Potential Single-Trial NDA Pathway

News · Aug 04, 2026
4

Decoy Therapeutics Expands Global Patent Portfolio for Antiviral Technology, Strengthens Intellectual Property Around D-MAV and IMP³ACT Platform

News · Aug 04, 2026
5

Chugai Pharmaceutical Becomes Healthcare Innovation Partner of Japan Basketball Association, Advance Sports and Health

News · Aug 04, 2026
The signal
The week in pharma, distilled

One considered email — the stories, moves and numbers that matter, every Friday.

More from Pharma News

All stories →
Tonix Plans Adaptive Phase 2 Trial for Seasonal Lyme Disease Prevention Therapy, Advances Program Following FDA Type C Meeting
News

Tonix Plans Adaptive Phase 2 Trial for Seasonal Lyme Disease Prevention Therapy, Advances Program Following FDA Type C Meeting

Vaibhavi M. · Aug 04, 2026
Medicus Pharma Appoints Dr. Faisal Mehmud as CEO of UK Subsidiary Antev, Strengthens Leadership to Advance Global Development of Teverelix®
News

Medicus Pharma Appoints Dr. Faisal Mehmud as CEO of UK Subsidiary Antev, Strengthens Leadership to Advance Global Development of Teverelix®

Vaibhavi M. · Aug 04, 2026
Acurx Receives Positive FDA Feedback on Ibezapolstat Phase 3 Development Program, FDA Signals Potential Single-Trial NDA Pathway
News

Acurx Receives Positive FDA Feedback on Ibezapolstat Phase 3 Development Program, FDA Signals Potential Single-Trial NDA Pathway

Vaibhavi M. · Aug 04, 2026